The Decentralized Clinical Operations for Healthcare Research program is designed to strengthen decentralized clinical research in support of FDA-regulated products. The federal government will have access to Walgreens’ clinical trial ecosystem, which is designed to make clinical trials more accessible. It has reached more than 5 million patients over the last two years.
Walgreens has helped clinical trials meet recruitment goals and surpassed national averages for diverse participant recruiting in sponsor-led clinical trials. The company takes a comprehensive approach to recruiting participants and encourages engagement with its decentralized platform. These results stand out, given nearly 80% of clinical trials fail to meet enrollment goals and just 5% of the U.S. population participates in clinical trials.
The five-year partnership is valued at up to $100 million for the Decentralized Clinical Operations for Healthcare and Research program.
Walgreens and the Biomedical Advanced Research and Development Authority are also collaborating on a Phase 4 observational COVID-19 trial.
